Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP) - 14/04/16
Abstract |
Background |
The use of rituximab for refractory autoimmune blistering diseases is increasing. Data related to rituximab for the treatment of mucous membrane pemphigoid (MMP) are limited.
Objective |
We sought to compare the efficacy of adding rituximab with traditional immunosuppressive therapies in the treatment of MMP. The primary outcome was achievement and time to disease control.
Methods |
Patients with a diagnosis of MMP from August 2001 to June 2015 who had greater than 6 months of follow-up after the initiation of therapy were reviewed.
Results |
In all, 24 patients were treated with rituximab and 25 were treated with conventional immunosuppression. Of patients, 100% in the rituximab group achieved disease control compared with 40% in the conventional group (P < .01), with a mean time to disease control of 10.17 months and 37.7 months (P = .02). Adverse events were seen in 33% of patients after rituximab, compared with 48% of patients in the conventional group (P = .2).
Limitations |
Rituximab dosing was not uniform and the 2 groups were not matched in terms of disease severity, nor were they randomized.
Conclusions |
Our study indicates that the addition of rituximab to conventional therapy in patients with MMP results in more rapid and sustained disease control with potentially fewer adverse events.
Le texte complet de cet article est disponible en PDF.Key words : autoimmune blistering disease, cicatricial pemphigoid, immunosuppression, mucous membrane pemphigoid, ocular pemphigoid, rituximab
Plan
| Dr Feldman was the recipient of the Dermatology Foundation's Medical Dermatology Career Development Award, 2013-2016. |
|
| Conflicts of interest: None declared. |
Vol 74 - N° 5
P. 835-840 - mai 2016 Retour au numéro
Article précédent
- A New Section for JAAD
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
- Kim A. Papp, James G. Krueger, Steven R. Feldman, Richard G. Langley, Diamant Thaci, Hideshi Torii, Stephen Tyring, Robert Wolk, Annie Gardner, Charles Mebus, Huaming Tan, Yingchun Luo, Pankaj Gupta, Lotus Mallbris, Svitlana Tatulych
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?